U.S. COMPANY FILING
ASTRAZENECA LICENSES NOVEL EGFR INHIBITOR
Filing text preview
AstraZeneca entered an exclusive global license agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), a novel oral EGFR inhibitor for lung cancer. Zegfrovy is approved in the US and China for NSCLC with EGFR exon 20 insertion mutations. AstraZeneca will pay $600M upfront, up to $900M in milestones, and tiered royalties. The deal is expected to close in H2 2026 and does not impact 2026 guidance.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record